A working taxonomy of Google Merchant Center disapprovals for Indian supplement brands

Search for Google Merchant Center compliance advice and nearly everything returned assumes a US context: FDA structure/function claim language, FTC substantiation standards, DSHEA labelling categories. None of it is wrong, and none of it is what actually governs an Indian supplement brand's product pages, because the product itself is regulated by FSSAI, not FDA, and the labelling law that determines whether a claim is even legal to make has nothing to do with the US framework most guides quote.

This matters because Google's own policy, the unapproved-substances and healthcare-and-medicines rules that actually gate a listing's approval, is regulator-agnostic in its wording but not in its enforcement pattern: what triggers a disapproval in practice is a mismatch between what's claimed and what's approved, and "approved" means something different depending on which country's regulator issued the approval. An Indian brand copying a US compliance checklist is checking against the wrong law while believing it's being careful.

Google's Merchant Center policy on unapproved pharmaceuticals and supplements prohibits listings for products making disease-treatment or disease-prevention claims without regulatory approval for that specific use, and separately prohibits a defined list of substance categories outright regardless of claims made: unapproved weight-loss formulations, ephedra-based products, anabolic steroids and prohormones, and several others [1]. The healthcare-and-medicines policy layered on top of this restricts how any health-adjacent product, approved or not, can be marketed: claims that a product prevents, treats, or cures a named condition are restricted even for products that are otherwise compliant, because the claim itself, not just the ingredient, is the thing being policed [2].

The practical reading: a product can be fully FSSAI-compliant, correctly labelled, and legally sellable in India, and still be disapproved on Google Shopping because its on-page marketing copy names a medical condition next to a specific claimed outcome. Compliance with the regulator that governs the product and compliance with the platform that lists it are two separate checks, and most Indian supplement brands only ever run the first one.

The categories below are not theoretical. They come from a full compliance pass run across a live six-product Shopify supplement catalogue, scored 0 to 10 per product page against disapproval risk, which returned 64 distinct flags and one live labelling violation already visible on the site before the audit found it [3]. Presented here as a reusable taxonomy rather than a one-brand report, because the pattern generalises further than the one catalogue it was found in.

A workable severity model treats each flag on a 0-10 scale per product page, weighted by two factors: how directly the flag maps to Google's stated policy language (a named condition beside a claim scores higher than an ambiguous adjective), and how easily an automated reviewer would catch it versus a human one, since Google's own review process is a mix of both and the automated pass runs first and more often. In the audit this taxonomy is drawn from, the worst-scoring page reached 8 of 10 specifically because it combined two conditions at once, PCOS and fertility, directly beside a specific clinical-dose claim, the exact pattern the condition-naming-proximity category above describes [3].

This taxonomy reflects Google's policy language and enforcement pattern as observed through 2026 audit work; Google updates unapproved-substances and healthcare policy periodically, and a category that is a minor flag today can become a hard block after a policy revision with no announcement most sellers see in time. This is not a Google-endorsed standard, and it is not a substitute for FSSAI legal review, which governs whether a claim can be made at all, independent of whether Google happens to approve the listing that makes it. A brand using this taxonomy should treat it as a first pass that catches the patterns most likely to cost a listing, not as a complete compliance sign-off.